Oral antipsychotic (AP) medications are frequently prescribed to people with bipolar I disorder (BD-I). A cross-sectional online survey examined the experiences of people living with BD-I with a history of recent AP use. Adults with self-reported physician-diagnosed BD-I (N = 200) who received oral APs during the prior year completed a survey on AP-related experiences, including side effects and their perceived burden on social functioning, adherence, and work. Items also assessed preferences for trade-offs (balancing symptom management and side effects) when considering a hypothetical new AP. The perceived impact of specific, prevalent side effects on adherence, work, and preferences for a hypothetical AP were also examined. Analyses were descriptive. The survey sample had a mean age of 43.2 (SD = 12.4) years, was 60% female, and 31% nonwhite. Almost all participants (98%) had experienced AP side effects. Common self-reported side effects were feeling drowsy or tired (83%), lack of emotion (79%), anxiety (79%), dry mouth (76%), and weight gain (76%). Weight gain was cited as the most bothersome side effect, rated by most participants (68%) as “very” or “extremely bothersome.” Nearly half of participants (49%) reported that AP side effects negatively impacted their job performance; almost all (92%) reported that side effects – most commonly anxiety and lack of emotion – negatively impacted social relationships (e.g., family or romantic partners). The most commonly-reported reason for stopping AP use was dislike of side effects (48%). Side effects most likely to lead to stopping or taking less of AP treatment included “feeling like a ‘zombie’” (29%), feeling drowsy or tired (25%), and weight gain (24%). When considering a hypothetical new AP, the most common side effects participants wanted to avoid included AP-induced anxiety (50%), weight gain (48%), and “feeling like a ‘zombie’” (47%). Side effects of APs were both common and bothersome, and impacted social functioning, adherence, and work. Findings highlight the prevailing unmet need for new APs with more favorable benefit-risk profiles.

中文翻译：

---

I型双相情感障碍患者的抗精神病治疗经验：在线调查的患者观点。

经常向患有双相性I型障碍（BD-I）的人开具口服抗精神病药（AP）。一项横断面在线调查调查了有近期AP使用史的BD-I患者的经历。自我报告为医生诊断的BD-I成年人（N = 200）在上一年接受口服AP的成年人完成了与AP相关经历的调查，包括副作用及其对社会功能，依从性和工作的感知负担。在考虑假设的新AP时，项目还评估了权衡的偏好（平衡症状管理和副作用）。还检查了特定，普遍的副作用对假设的AP的依从性，工作和偏好的感知影响。分析是描述性的。调查样本的平均年龄为43.2（SD = 12.4）岁，女性为60％，非白人为31％。几乎所有参与者（98％）都经历过AP副作用。自我报告的常见副作用为昏昏欲睡或疲倦（83％），情绪低落（79％），焦虑症（79％），口干（76％）和体重增加（76％）。体重增加被认为是最令人讨厌的副作用，大多数参与者（68％）将其评为“非常”或“极其令人讨厌”。近一半的参与者（49％）报告说，AP副作用对他们的工作表现产生了负面影响；几乎所有（92％）的人都说副作用-最常见的是焦虑和缺乏情感-对社会关系（例如家庭或恋爱伴侣）产生了负面影响。停止使用AP的最常见原因是不喜欢副作用（48％）。最有可能导致停止或少用AP治疗的副作用包括“感觉像'僵尸'”（29％），昏昏欲睡或疲倦（25％），和体重增加（24％）。在考虑假设的新型AP时，参与者最想避免的副作用包括AP引起的焦虑（50％），体重增加（48％）和“感觉像“僵尸””（47％）。AP的副作用既常见又麻烦，并且影响了社会功能，依从性和工作。调查结果突出显示了对新的受影响人口普遍存在的尚未满足的需求，这些需求具有更有利的利益风险特征。